These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine. Johansson BE Vaccine; 1999 Apr; 17(15-16):2073-80. PubMed ID: 10217609 [TBL] [Abstract][Full Text] [Related]
3. A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine. Ryder AB; Buonocore L; Vogel L; Nachbagauer R; Krammer F; Rose JK J Virol; 2015 Mar; 89(5):2820-30. PubMed ID: 25540378 [TBL] [Abstract][Full Text] [Related]
4. Protection of mice against a lethal influenza challenge by immunization with yeast-derived recombinant influenza neuraminidase. Martinet W; Saelens X; Deroo T; Neirynck S; Contreras R; Min Jou W; Fiers W Eur J Biochem; 1997 Jul; 247(1):332-8. PubMed ID: 9249044 [TBL] [Abstract][Full Text] [Related]
5. Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAs. Chen Z; Matsuo K; Asanuma H; Takahashi H; Iwasaki T; Suzuki Y; Aizawa C; Kurata T; Tamura S Vaccine; 1999 Feb; 17(7-8):653-9. PubMed ID: 10067670 [TBL] [Abstract][Full Text] [Related]
6. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus. Smith GE; Flyer DC; Raghunandan R; Liu Y; Wei Z; Wu Y; Kpamegan E; Courbron D; Fries LF; Glenn GM Vaccine; 2013 Sep; 31(40):4305-13. PubMed ID: 23891795 [TBL] [Abstract][Full Text] [Related]
7. In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran. Ebrahimi SM; Dabaghian M; Tebianian M; Jazi MH Virology; 2012 Aug; 430(1):63-72. PubMed ID: 22595444 [TBL] [Abstract][Full Text] [Related]
9. Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant. Beljanski V; Chiang C; Kirchenbaum GA; Olagnier D; Bloom CE; Wong T; Haddad EK; Trautmann L; Ross TM; Hiscott J J Virol; 2015 Oct; 89(20):10612-24. PubMed ID: 26269188 [TBL] [Abstract][Full Text] [Related]
10. Recombinant secreted haemagglutinin protects mice against a lethal challenge of influenza virus. Vanlandschoot P; Maertens G; Jou WM; Fiers W Vaccine; 1993 Sep; 11(12):1185-7. PubMed ID: 8256499 [TBL] [Abstract][Full Text] [Related]
11. Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain. de Wit E; Munster VJ; Spronken MI; Bestebroer TM; Baas C; Beyer WE; Rimmelzwaan GF; Osterhaus AD; Fouchier RA J Virol; 2005 Oct; 79(19):12401-7. PubMed ID: 16160167 [TBL] [Abstract][Full Text] [Related]
12. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system. Brett IC; Johansson BE Virology; 2005 Sep; 339(2):273-80. PubMed ID: 15996702 [TBL] [Abstract][Full Text] [Related]
13. Antibody responses and protection against influenza virus infection in different congenic strains of mice immunized intranasally with adjuvant-combined A/Beijing/262/95 (H1N1) virus hemagglutinin or neuraminidase. Yoshikawa T; Suzuki Y; Nomoto A; Sata T; Kurata T; Tamura Si Vaccine; 2002 Nov; 21(1-2):60-6. PubMed ID: 12443663 [TBL] [Abstract][Full Text] [Related]
14. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Huleatt JW; Nakaar V; Desai P; Huang Y; Hewitt D; Jacobs A; Tang J; McDonald W; Song L; Evans RK; Umlauf S; Tussey L; Powell TJ Vaccine; 2008 Jan; 26(2):201-14. PubMed ID: 18063235 [TBL] [Abstract][Full Text] [Related]
15. Protection of pigs against pandemic swine origin H1N1 influenza A virus infection by hemagglutinin- or neuraminidase-expressing attenuated pseudorabies virus recombinants. Klingbeil K; Lange E; Blohm U; Teifke JP; Mettenleiter TC; Fuchs W Virus Res; 2015 Mar; 199():20-30. PubMed ID: 25599604 [TBL] [Abstract][Full Text] [Related]
16. Beta 2-microglobulin-deficient mice can be protected against influenza A infection by vaccination with vaccinia-influenza recombinants expressing hemagglutinin and neuraminidase. Epstein SL; Misplon JA; Lawson CM; Subbarao EK; Connors M; Murphy BR J Immunol; 1993 Jun; 150(12):5484-93. PubMed ID: 8390536 [TBL] [Abstract][Full Text] [Related]
17. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses. Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745 [TBL] [Abstract][Full Text] [Related]
18. Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets. Smith GE; Sun X; Bai Y; Liu YV; Massare MJ; Pearce MB; Belser JA; Maines TR; Creager HM; Glenn GM; Flyer D; Pushko P; Levine MZ; Tumpey TM Virology; 2017 Sep; 509():90-97. PubMed ID: 28624679 [TBL] [Abstract][Full Text] [Related]
19. An H1-H3 chimeric influenza virosome confers complete protection against lethal challenge with PR8 (H1N1) and X47 (H3N2) viruses in mice. Abdoli A; Soleimanjahi H; Tavassoti Kheiri M; Jamali A; Mazaheri V; Abdollahpour Alitappeh M Pathog Dis; 2014 Dec; 72(3):197-207. PubMed ID: 25066138 [TBL] [Abstract][Full Text] [Related]
20. Baculovirus-produced influenza virus-like particles in mammalian cells protect mice from lethal influenza challenge. Tang XC; Lu HR; Ross TM Viral Immunol; 2011 Aug; 24(4):311-9. PubMed ID: 21830902 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]